$2.27 Million in Sales Expected for Yumanity Therapeutics, Inc. (NASDAQ:YMTX) This Quarter

Wall Street brokerages forecast that Yumanity Therapeutics, Inc. (NASDAQ:YMTX) will report $2.27 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Yumanity Therapeutics’ earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $3.50 million. The company is expected to issue its next quarterly earnings results on Thursday, August 5th.

According to Zacks, analysts expect that Yumanity Therapeutics will report full-year sales of $10.08 million for the current fiscal year, with estimates ranging from $6.50 million to $14.03 million. For the next fiscal year, analysts forecast that the firm will report sales of $9.56 million, with estimates ranging from $4.00 million to $14.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Yumanity Therapeutics.

Yumanity Therapeutics (NASDAQ:YMTX) last issued its quarterly earnings results on Thursday, May 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.01). The firm had revenue of $3.53 million during the quarter, compared to the consensus estimate of $1.00 million.

A number of equities research analysts recently weighed in on the company. HC Wainwright assumed coverage on Yumanity Therapeutics in a research report on Friday, June 4th. They set a “buy” rating and a $39.00 target price on the stock. Zacks Investment Research downgraded Yumanity Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 4th. Finally, Jefferies Financial Group assumed coverage on Yumanity Therapeutics in a research report on Thursday, April 1st. They set a “buy” rating and a $35.00 target price on the stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ikarian Capital LLC lifted its stake in Yumanity Therapeutics by 65.6% during the first quarter. Ikarian Capital LLC now owns 219,470 shares of the company’s stock worth $3,972,000 after purchasing an additional 86,956 shares during the period. Artal Group S.A. bought a new position in Yumanity Therapeutics during the fourth quarter worth about $3,696,000. Sphera Funds Management LTD. lifted its stake in Yumanity Therapeutics by 59.9% during the first quarter. Sphera Funds Management LTD. now owns 208,609 shares of the company’s stock worth $3,776,000 after purchasing an additional 78,175 shares during the period. Stonepine Capital Management LLC bought a new position in Yumanity Therapeutics during the fourth quarter worth about $1,850,000. Finally, Pura Vida Investments LLC bought a new position in shares of Yumanity Therapeutics in the first quarter valued at approximately $1,246,000.

YMTX stock traded up $0.25 during trading on Tuesday, reaching $16.08. 100 shares of the stock were exchanged, compared to its average volume of 73,876. Yumanity Therapeutics has a twelve month low of $13.52 and a twelve month high of $36.80. The firm has a market capitalization of $164.06 million, a P/E ratio of -0.73 and a beta of 0.73. The business’s 50 day simple moving average is $16.20. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.61 and a quick ratio of 3.61.

Yumanity Therapeutics Company Profile

Yumanity Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases.

Further Reading: Cost of Equity

Get a free copy of the Zacks research report on Yumanity Therapeutics (YMTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Yumanity Therapeutics (NASDAQ:YMTX)

Receive News & Ratings for Yumanity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yumanity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.